Efficiency of Tadalafil for Management of Female Sexual Dysfunction

Efficiency of Tadalafil for Management of Female Sexual Dysfunction in Females With Genital Mutilation

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05266651

Enrollment

Registered

2022-03-04

Start date

2022-03-10

Completion date

2022-05-31

Last updated

2022-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual Dysfunction

Keywords

female genital mutilation, Sexual dysfunction, Clitoral artery Doppler

Brief summary

comparative study between tadalafil versus placebo effect for the management of circumsized female

Detailed description

the group of patient will be randomly divided into 2 groups, half of the patients will receive tadalafil and the other half will receive placebo

Interventions

DRUGTadalafil 5mg

oral tablets for one month duration

DRUGPlacebo

oral tablets for one month duration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 35 Years

Healthy volunteers

Inclusion criteria

* female with history of female genital mutilation female with history of sexual dysfunction

Exclusion criteria

* any medical disorder

Design outcomes

Primary

Measure	Time frame	Description
clitorial Artery Doppler	after one month duration of drug use	Pulsatile index
Clitorial artery doppler	after one month duration of drug use	Resistance index

Secondary

Measure	Time frame	Description
score of sexual function	after on month of the drug use	arousal orgasm frequency

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026